Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Bayer anticoagulant results published

Bayer anticoagulant results published

26th June 2008

Trials involving more than 7,000 patients show that the drug rivaroxaban is a better treatment to prevent blood clotting than one currently approved for the market.

Sanofi-Aventis’s Enoxaparin is the current standard for preventing blood clots in patients who have had major orthopaedic surgery.

Bayer HealthCare says the findings from its two trials show rivaroxaban is significantly more effective.

The results from the phase III Record studies have been published in the New England Journal of Medicine.

Bengt Eriksson at the Sahlgrenska University Hospital in Sweden was the principal investigator of one of the clinical trial.

He said: “This is of great importance since patients undergoing major surgery of the hip and knee are at high risk of developing such potentially life threatening complications and the risk of VTE extends beyond hospitalisation.”

Rivaroxaban is being developed by Bayer with Johnson & Johnson Pharmaceutical Research & Development.

Enoxaparin injections, marketed as Lovenox or Clexane, are derived from mucous membranes in the intestines of pigs.

We currently have 7 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.